Abeona Therapeutics Inc. reported full year 2025 financial results including total revenue of $5.8 million, net income of $71.2 million driven by $152.4 million gain from PRV sale, and cash, cash equivalents and short-term investments of $191.4 million as of December 31, 2025. ZEVASKYN commercial launch progressed with first patient treatment completed in December 2025.
Key takeaways
Total revenue $5.8 million for year ended December 31, 2025 vs $0 in 2024
Net product revenue $2.4 million from single ZEVASKYN treatment in December 2025
Net income $71.2 million or $1.34 basic EPS vs net loss $63.7 million or $(1.55) EPS in 2024
Cash, cash equivalents and short-term investments $191.4 million as of December 31, 2025
Gain from PRV sale $152.4 million net of $2.6 million costs from $155.0 million gross proceeds
R&D expenses $26.8 million decreased $7.6 million from 2024; SG&A $65.0 million increased $35.1 million